<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Anakinra</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00026</strong>&#160; (BIOD00060, BTD00060)</td></tr><tr><th>Type</th><td>biotech</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Anakinra is a recombinant, nonglycosylated human interleukin-1 receptor antagonist (IL-1Ra). The difference  between anakinra and the native human IL-1Ra is that anakinra has an extra methionine residue at the amino terminus. It is manufactured by using the E. coli expression system. Anakinra is composed of 153 amino acid residues. <span class="caps">FDA</span> approved on November 14, 2001.</p></td></tr><tr><th>Protein structure</th><td><a href="/system/protein_structures/full/DB00026.png?1266600378"><img alt="Db00026" src="/system/protein_structures/thumb/DB00026.png?1266600378"></a></td></tr><tr><th>Protein chemical formula</th><td>C<sub>759</sub>H<sub>1186</sub>N<sub>208</sub>O<sub>232</sub>S<sub>10</sub></td></tr><tr><th>Protein average weight</th><td>17257.6000</td></tr><tr><th>Sequences</th><td><pre class="sequence">&gt;DB00026 sequence
MRPSGRKSSKMQAFRIWDVNQKTFYLRNNQLVAGYLQGPNVNLEEKIDVVPIEPHALFLG
IHGGKMCLSCVKSGDETRLQLEAVNITDLSENRKQDKRFAFIRSDSGPTTSFESAACPGW
FLCTAMEADQPVSLTNMPDEGVMVTKFYFQEDE</pre><small><a class="btn btn-info btn-sm" href="/drugs/DB00026/polypeptide_sequences.fasta">Download FASTA Format</a></small></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>ICIL-1RA</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>IL-1ra</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>IL-1RN</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>IL1 inhibitor</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Interleukin-1 receptor antagonist protein precursor</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>IRAP</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Kineret</td><td>Amgen Inc</td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antirheumatic-agents">Antirheumatic Agents</a></li>
<li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>143090-92-0</td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Organic Acids</td></tr><tr><th>Class</th><td>Carboxylic Acids and Derivatives</td></tr><tr><th>Subclass</th><td>Amino Acids, Peptides, and Analogues</td></tr><tr><th>Direct parent</th><td>Peptides</td></tr><tr><th>Alternative parents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Substituents</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Classification description</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of adult rheumatoid arthritis and treatment of Neonatal-Onset Multisystem Inflammatory Disease (NOMID). </td></tr><tr><th>Pharmacodynamics</th><td>Used to treat rheumatoid arthritis, Anakinra blocks the biologic activity of IL-1 by competitively inhibiting IL-1 binding to the interleukin-1 type I receptor (IL-1RI), which is expressed in a wide variety of tissues and organs. IL-1 production is induced in response to inflammatory stimuli and mediates various physiologic responses including inflammatory and immunological responses. Patients with rheumatoid arthritis have elevated levels of IL-1. The levels of the naturally occurring IL-1Ra in synovium and synovial fluid from rheumatoid arthritis (RA) patients are not sufficient to compete with the elevated amount of locally produced IL-1. Increasing the levels of IL-1Ra by artificial means reduces the negative effects (cartilage degradation, bone resorption) of IL-1.</td></tr><tr><th>Mechanism of action</th><td>Anakinra binds competitively to the Interleukin-1 type I receptor (IL-1RI), thereby inhibiting the action of elevated levels IL-1 which normally can lead to cartilage degradation and bone resorption.</td></tr><tr><th>Absorption</th><td>When a 70 mg subcutaneous bolus injection is given to healthy subjects, the absolute bioavailability is 95%. Accumulation does not occur following daily subcutaneous doses. 
Tmax, SubQ, 1-2 mg/kg, healthy subjects = 3-7 hours;
Cmax, SubQ, 3 mg/kg once daily, NOMID patients = 3628 ng/mL. 
</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Metabolism</th><td class="data-table-container"></td></tr><tr><th>Route of elimination</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Half life</th><td>Healthy subjects = 4 - 6 hours;
NOMID patients = 5.7 hours (range of 3.1 - 28.2 hours). </td></tr><tr><th>Clearance</th><td><p>Clearance is variable and increases with increasing creatinine clearance and body weight. However, gender and age were not significant factors.</p></td></tr><tr><th>Toxicity</th><td>Most common adverse reactions (incidence &#8805; 5%) are injection site reaction, worsening of rheumatoid arthritis, upper respiratory tract infection, headache, nausea, diarrhea, sinusitis, arthralgia, flu like-symptoms, and abdominal pain when anakinra is used in RA patients. In NOMID patients, the most common AEs during the first 6 months of treatment (incidence &gt;10%) are injection site reaction, headache, vomiting, arthralgia, pyrexia, and nasopharyngitis. </td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.amgen.com">Amgen Inc.</a></li>
<li><a href="http://www.biovitrum.com">BioVitrum AB</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Injection, solution</td><td>Subcutaneous</td><td>10MIU/VIAL; 18MIU/VIAL; 25MIU/VIAL   </td></tr></tbody></table></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB06168">Canakinumab</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB08904">Certolizumab pegol</a></td><td>Co-administration with other TNF-blocking agents may increase the risk of serious infections. Concomitant therapy is not recommended. </td></tr><tr><td><a href="/drugs/DB06674">golimumab</a></td><td>Avoid combination with anakinra due to the increased chance of serious infection.
</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>results in increased immunosuppressive effects; increases the risk of infection. </td></tr><tr><td><a href="/drugs/DB01041">Thalidomide</a></td><td>Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB08895">Tofacitinib</a></td><td>Avoid combination due to the potential increase in tofacitinib related adverse effects.
</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>